A share price of Janux Therapeutics Inc [JANX] is currently trading at $22.72, down -1.43%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The JANX shares have lost -6.50% over the last week, with a monthly amount drifted -5.39%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Janux Therapeutics Inc [NASDAQ: JANX] stock has seen the most recent analyst activity on August 19, 2025, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $42. Previously, Raymond James started tracking the stock with Outperform rating on July 11, 2025, and set its price target to $65. On December 03, 2024, H.C. Wainwright reiterated its Buy rating and revised its price target to $70 on the stock. BTIG Research reiterated its Buy rating and increased its price target to $100 on December 03, 2024. Leerink Partners initiated its recommendation with a Outperform and recommended $79 as its price target on November 22, 2024. UBS started tracking with a Buy rating for this stock on October 24, 2024, and assigned it a price target of $69. In a note dated September 06, 2024, Stifel initiated an Buy rating and provided a target price of $70 on this stock.
Janux Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $21.97 and $71.71. Currently, Wall Street analysts expect the stock to reach $65 within the next 12 months. Janux Therapeutics Inc [NASDAQ: JANX] shares were valued at $22.72 at the most recent close of the market. An investor can expect a potential return of 186.09% based on the average JANX price forecast.
Analyzing the JANX fundamentals
Trailing Twelve Months sales for Janux Therapeutics Inc [NASDAQ:JANX] were 0.44M which represents -100.00% decline. Gross Profit Margin for this corporation currently stands at 1.26% with Operating Profit Margin at 17.95%, Pretax Profit Margin comes in at 13.09%, and Net Profit Margin reading is 13.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is -0.11 and Total Capital is -0.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.24 points at the first support level, and at 21.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.41, and for the 2nd resistance point, it is at 24.11.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Janux Therapeutics Inc [NASDAQ:JANX] is 47.03. As well, the Quick Ratio is 47.03, while the Cash Ratio is 2.45. Considering the valuation of this stock, the price to sales ratio is 3103.02, the price to book ratio is 1.36.
Transactions by insiders
Recent insider trading involved Meyer Andrew Hollman, Chief Business Officer, that happened on May 01 ’25 when 3333.0 shares were sold. Officer, ANDREW MEYER completed a deal on May 01 ’25 to buy 3333.0 shares. Meanwhile, Chief Business Officer Meyer Andrew Hollman sold 3334.0 shares on Apr 21 ’25.
